808 related articles for article (PubMed ID: 25186731)
1. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.
Huang J; Kang BH; Pancera M; Lee JH; Tong T; Feng Y; Imamichi H; Georgiev IS; Chuang GY; Druz A; Doria-Rose NA; Laub L; Sliepen K; van Gils MJ; de la Peña AT; Derking R; Klasse PJ; Migueles SA; Bailer RT; Alam M; Pugach P; Haynes BF; Wyatt RT; Sanders RW; Binley JM; Ward AB; Mascola JR; Kwong PD; Connors M
Nature; 2014 Nov; 515(7525):138-42. PubMed ID: 25186731
[TBL] [Abstract][Full Text] [Related]
2. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
[TBL] [Abstract][Full Text] [Related]
3. Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.
Wibmer CK; Gorman J; Ozorowski G; Bhiman JN; Sheward DJ; Elliott DH; Rouelle J; Smira A; Joyce MG; Ndabambi N; Druz A; Asokan M; Burton DR; Connors M; Abdool Karim SS; Mascola JR; Robinson JE; Ward AB; Williamson C; Kwong PD; Morris L; Moore PL
PLoS Pathog; 2017 Jan; 13(1):e1006074. PubMed ID: 28076415
[TBL] [Abstract][Full Text] [Related]
4. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.
Zhang MY; Yuan T; Li J; Rosa Borges A; Watkins JD; Guenaga J; Yang Z; Wang Y; Wilson R; Li Y; Polonis VR; Pincus SH; Ruprecht RM; Dimitrov DS
PLoS One; 2012; 7(9):e44241. PubMed ID: 22970187
[TBL] [Abstract][Full Text] [Related]
6. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
Chakrabarti BK; Pancera M; Phogat S; O'Dell S; McKee K; Guenaga J; Robinson J; Mascola J; Wyatt RT
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):877-87. PubMed ID: 21158699
[TBL] [Abstract][Full Text] [Related]
7. Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike.
Lee JH; Leaman DP; Kim AS; Torrents de la Peña A; Sliepen K; Yasmeen A; Derking R; Ramos A; de Taeye SW; Ozorowski G; Klein F; Burton DR; Nussenzweig MC; Poignard P; Moore JP; Klasse PJ; Sanders RW; Zwick MB; Wilson IA; Ward AB
Nat Commun; 2015 Sep; 6():8167. PubMed ID: 26404402
[TBL] [Abstract][Full Text] [Related]
8. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
[TBL] [Abstract][Full Text] [Related]
9. Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site.
Crooks ET; Tong T; Chakrabarti B; Narayan K; Georgiev IS; Menis S; Huang X; Kulp D; Osawa K; Muranaka J; Stewart-Jones G; Destefano J; O'Dell S; LaBranche C; Robinson JE; Montefiori DC; McKee K; Du SX; Doria-Rose N; Kwong PD; Mascola JR; Zhu P; Schief WR; Wyatt RT; Whalen RG; Binley JM
PLoS Pathog; 2015 May; 11(5):e1004932. PubMed ID: 26023780
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.
Zhou T; Georgiev I; Wu X; Yang ZY; Dai K; Finzi A; Kwon YD; Scheid JF; Shi W; Xu L; Yang Y; Zhu J; Nussenzweig MC; Sodroski J; Shapiro L; Nabel GJ; Mascola JR; Kwong PD
Science; 2010 Aug; 329(5993):811-7. PubMed ID: 20616231
[TBL] [Abstract][Full Text] [Related]
11. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus.
Liao HX; Lynch R; Zhou T; Gao F; Alam SM; Boyd SD; Fire AZ; Roskin KM; Schramm CA; Zhang Z; Zhu J; Shapiro L; ; Mullikin JC; Gnanakaran S; Hraber P; Wiehe K; Kelsoe G; Yang G; Xia SM; Montefiori DC; Parks R; Lloyd KE; Scearce RM; Soderberg KA; Cohen M; Kamanga G; Louder MK; Tran LM; Chen Y; Cai F; Chen S; Moquin S; Du X; Joyce MG; Srivatsan S; Zhang B; Zheng A; Shaw GM; Hahn BH; Kepler TB; Korber BT; Kwong PD; Mascola JR; Haynes BF
Nature; 2013 Apr; 496(7446):469-76. PubMed ID: 23552890
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.
Zhang MY; Xiao X; Sidorov IA; Choudhry V; Cham F; Zhang PF; Bouma P; Zwick M; Choudhary A; Montefiori DC; Broder CC; Burton DR; Quinnan GV; Dimitrov DS
J Virol; 2004 Sep; 78(17):9233-42. PubMed ID: 15308718
[TBL] [Abstract][Full Text] [Related]
13. Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL.
Kumar R; Pan R; Upadhyay C; Mayr L; Cohen S; Wang XH; Balasubramanian P; Nádas A; Seaman MS; Zolla-Pazner S; Gorny MK; Kong XP; Hioe CE
J Virol; 2015 Sep; 89(17):9090-102. PubMed ID: 26109728
[TBL] [Abstract][Full Text] [Related]
14. Neutralization resistance of virological synapse-mediated HIV-1 Infection is regulated by the gp41 cytoplasmic tail.
Durham ND; Yewdall AW; Chen P; Lee R; Zony C; Robinson JE; Chen BK
J Virol; 2012 Jul; 86(14):7484-95. PubMed ID: 22553332
[TBL] [Abstract][Full Text] [Related]
15. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
[TBL] [Abstract][Full Text] [Related]
16. Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method.
Evans MC; Phung P; Paquet AC; Parikh A; Petropoulos CJ; Wrin T; Haddad M
BMC Bioinformatics; 2014 Mar; 15():77. PubMed ID: 24646213
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing Antibodies Induced by First-Generation gp41-Stabilized HIV-1 Envelope Trimers and Nanoparticles.
Kumar S; Lin X; Ngo T; Shapero B; Sou C; Allen JD; Copps J; Zhang L; Ozorowski G; He L; Crispin M; Ward AB; Wilson IA; Zhu J
mBio; 2021 Jun; 12(3):e0042921. PubMed ID: 34156262
[TBL] [Abstract][Full Text] [Related]
18. HIV vaccine design and the neutralizing antibody problem.
Burton DR; Desrosiers RC; Doms RW; Koff WC; Kwong PD; Moore JP; Nabel GJ; Sodroski J; Wilson IA; Wyatt RT
Nat Immunol; 2004 Mar; 5(3):233-6. PubMed ID: 14985706
[No Abstract] [Full Text] [Related]
19. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing.
Wu X; Zhou T; Zhu J; Zhang B; Georgiev I; Wang C; Chen X; Longo NS; Louder M; McKee K; O'Dell S; Perfetto S; Schmidt SD; Shi W; Wu L; Yang Y; Yang ZY; Yang Z; Zhang Z; Bonsignori M; Crump JA; Kapiga SH; Sam NE; Haynes BF; Simek M; Burton DR; Koff WC; Doria-Rose NA; Connors M; ; Mullikin JC; Nabel GJ; Roederer M; Shapiro L; Kwong PD; Mascola JR
Science; 2011 Sep; 333(6049):1593-602. PubMed ID: 21835983
[TBL] [Abstract][Full Text] [Related]
20. Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.
Prabakaran P; Gan J; Wu YQ; Zhang MY; Dimitrov DS; Ji X
J Mol Biol; 2006 Mar; 357(1):82-99. PubMed ID: 16426633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
